AstraZeneca PLC (STO:AZN)
Sweden · Delayed Price · Currency is SEK | Market Cap | 2.63T +10.5% |
| Revenue (ttm) | 547.72B +13.5% |
| Net Income | 88.56B +44.7% |
| EPS | 56.71 +45.0% |
| Shares Out | n/a |
| PE Ratio | 29.71 |
| Forward PE | 18.33 |
| Dividend | 32.77 (1.90%) |
| Ex-Dividend Date | Aug 7, 2025 |
| Volume | 1,081,747 |
| Average Volume | 333,612 |
| Open | 1,710.50 |
| Previous Close | 1,702.00 |
| Day's Range | 1,679.50 - 1,739.50 |
| 52-Week Range | 1,226.00 - 1,786.50 |
| Beta | 0.19 |
| RSI | 52.06 |
| Earnings Date | Feb 10, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial numbers in USD Financial StatementsNews
AstraZeneca Forecasts Continued Growth on Pipeline Strength
It anticipates 2026 revenue to grow by a mid-to-high single-digit percentage, and core earnings per share to climb by a low double-digit percentage.
AstraZeneca profit climbs on cancer and heart drug demand
The pharmaceutical giant announced profit in line with expectations and revenue that slightly beat forecasts on Tuesday.
Drugmaker AstraZeneca forecasts sales and profit growth in 2026
AstraZeneca on Tuesday forecast profit and sales growth in 2026, betting on demand for its cancer and cardiovascular treatments while the drugmaker pursues massive expansion in the U.S. and China.
A Look Ahead: AstraZeneca's Earnings Forecast
AstraZeneca (NASDAQ: AZN) will release its quarterly earnings report on Tuesday, 2026-02-10. Here's a brief overview for investors ahead of the announcement. Analysts anticipate AstraZeneca to report...
AstraZeneca PLC (LSE:AZN) Q4 2025 Earnings Report Preview: What To Expect
AstraZeneca PLC (LSE:AZN) Q4 2025 Earnings Report Preview: What To Expect
Oakmark International Strategy Q4 2025 New Investments And Divestments
Oakmark International Strategy Q4 2025 New Investments And Divestments
How Hong Kong can bring China and Britain closer: it’s not just finance
British Prime Minister Keir Starmer recently concluded his four-day visit to China, during which he met President Xi Jinping. He was accompanied by a sizeable delegation of prominent British business ...
Wall Street Week Ahead
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
Spotlight On Coca-Cola, Ford, AstraZeneca Earnings
Wall Street Week Ahead: track key earnings (KO, F, CSCO), IPOs, and data like retail sales & CPI—plus Bitcoin and ETF flows. Read here for more.
AstraZeneca (AZN) Among Major Drugmakers in Focus Amid Trump's Drug Pricing Plan
AstraZeneca (AZN) Among Major Drugmakers in Focus Amid Trump's Drug Pricing Plan
Company Diary: AstraZeneca, Barratt Redrow, Unilever
AstraZeneca, Barratt Redrow, Unilever are amongst the FTSE 350 and other companies reporting earnings for the week of 09 February
Levicept Announces the Appointment of James Sandy as Chief Development Officer
SANDWICH, United Kingdom, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), today annou...
AstraZeneca Stock Soared 103% Monday, Holding At High Level. Gets Rating Upgrade.
AstraZeneca saw its IBD SmartSelect Composite Rating rise to 96 Tuesday, up from 92 the day before.
AstraZeneca (AZN) Stock Surges Over 100%
AstraZeneca (AZN) Stock Surges Over 100%
AstraZeneca (AZN) Faces FDA Setback for Lupus Drug Saphnelo
AstraZeneca (AZN) Faces FDA Setback for Lupus Drug Saphnelo
AstraZeneca denied FDA approval for subcutaneous version of lupus drug
AstraZeneca gets FDA Complete Response Letter for subcutaneous Saphelo lupus treatment. Read more here.
AstraZeneca (AZN) Sees Significant Price Surge of Over 100%
AstraZeneca (AZN) Sees Significant Price Surge of Over 100%
AstraZeneca (AZN) Seeks FDA Approval for Expanded Cancer Therapy Use
AstraZeneca (AZN) Seeks FDA Approval for Expanded Cancer Therapy Use
FDA Rejects AstraZeneca's Saphnelo Injection, Shares Drop 1.9%
FDA Rejects AstraZeneca's Saphnelo Injection, Shares Drop 1.9%
Astra wins FDA priority review for Daiichi’s Datroway; denied approval for lupus therapy
AstraZeneca (AZN) stock is flat after FDA priority review for Datroway label expansion while injectable version of lupus drug Saphnelo is rejected. Read more here.
AstraZeneca (AZN) Awaits FDA Decision on Saphnelo Subcutaneous Application
AstraZeneca (AZN) Awaits FDA Decision on Saphnelo Subcutaneous Application
AstraZeneca (AZN) Gains Priority Review for Datroway in Cancer Treatment
AstraZeneca (AZN) Gains Priority Review for Datroway in Cancer Treatment
AstraZeneca's Initial Application for Lupus Injection Turned Down by FDA
The company is working with the U.S. regulator to move forward with an updated application, adding a decision is expected in the first half of 2026.
DATROWAY® Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy
Based on results from TROPION-Breast02 showing Daiichi Sankyo and AstraZeneca's DATROWAY significantly improved overall survival versus chemotherapy in this patient population If approved, DATROWAY co...
US FDA rejects AstraZeneca's easier-to-use version of lupus therapy
AstraZeneca said on Tuesday that the U.S. health regulator had rejected its application for an easier-to-use version of lupus therapy Saphnelo, pushing back the timeline for a possible approval to the...